14,364 Shares of Zoetis Inc. $ZTS Bought by McKinney Capital Management LLC

McKinney Capital Management LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 14,364 shares of the company’s stock, valued at approximately $1,003,000.

A number of other hedge funds also recently modified their holdings of the stock. Wealthfront Advisers LLC boosted its holdings in shares of Zoetis by 80.2% during the second quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after acquiring an additional 33,873 shares during the period. Pacer Advisors Inc. grew its position in shares of Zoetis by 16.7% in the first quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after purchasing an additional 23,687 shares during the last quarter. Diamond Hill Capital Management LLC Investment Advisor increased its stake in shares of Zoetis by 21.5% during the second quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock worth $255,637,000 after purchasing an additional 629,974 shares during the period. Nykredit A S bought a new position in shares of Zoetis during the second quarter worth approximately $10,042,000. Finally, Flossbach Von Storch SE acquired a new stake in Zoetis during the 2nd quarter worth approximately $302,601,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS traded up $0.69 during midday trading on Friday, hitting $83.65. The company’s stock had a trading volume of 3,151,935 shares, compared to its average volume of 4,644,448. The company has a quick ratio of 1.40, a current ratio of 2.35 and a debt-to-equity ratio of 2.51. Zoetis Inc. has a one year low of $68.77 and a one year high of $132.49. The stock has a market capitalization of $33.99 billion, a price-to-earnings ratio of 14.23, a price-to-earnings-growth ratio of 1.20 and a beta of 0.67. The company’s fifty day simple moving average is $76.28 and its two-hundred day simple moving average is $91.56.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.24. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. Zoetis’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.70 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a yield of 2.5%. Zoetis’s payout ratio is presently 36.05%.

Analyst Ratings Changes

Several research firms recently issued reports on ZTS. Morgan Stanley reduced their price target on Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a research note on Thursday, October 29th. TD Cowen lowered their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. Citigroup lowered their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Cantor Fitzgerald set a $94.00 target price on Zoetis in a report on Tuesday, August 25th. Finally, The Goldman Sachs Group started coverage on shares of Zoetis in a research report on Friday, October 16th. They issued a “neutral” rating and a $74.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $101.25.

Check Out Our Latest Research Report on ZTS

Zoetis Company Profile

(Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

See Also

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.